Published in Int J Oncol on February 01, 1995
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Respiration as the main determinant of carbon balance in European forests. Nature (2000) 5.07
Structure and expression of ubiquitin genes in higher plants. Eur J Biochem (1986) 2.82
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ (1992) 2.39
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res (1995) 2.14
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer (1997) 1.82
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A (1988) 1.76
Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet (1996) 1.75
Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer (1999) 1.71
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Rapid detection of Chlamydia trachomatis by an enzyme immunoassay method. Diagn Microbiol Infect Dis (1986) 1.50
c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer (1992) 1.46
Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet (1993) 1.38
Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer (1998) 1.28
ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene (1991) 1.27
The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet (2002) 1.26
HER2/neu amplification and comedo type breast carcinoma. Lancet (1989) 1.22
Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer (1991) 1.20
Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. Eur J Cancer (2000) 1.14
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res (1998) 1.12
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett (1994) 1.11
Natural infestation of the chewing lice (Werneckiella equi) on horses and treatment with imidacloprid and phoxim. Parasitol Res (2004) 1.09
Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer. Acta Oncol (1995) 1.05
Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat (1998) 1.05
Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer (1995) 1.04
Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer (1999) 1.04
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol (1989) 1.03
Infestation of Werneckiella equi on Icelandic horses, characteristics of predilection sites and lice dermatitis. Parasitol Res (2005) 1.02
Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol (1992) 1.01
High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer (2002) 1.00
Eruption of the nevado del ruiz volcano, Colombia, on 13 november 1985: tephra fall and lahars. Science (1986) 0.99
Gastric cancer after gastrectomy. Int J Cancer (1988) 0.98
Radiographic and clinical survey of degenerative joint disease in the distal tarsal joints in Icelandic horses. Equine Vet J (2000) 0.97
High frequency of allelic imbalance at chromosome region 16q22-23 in human breast cancer: correlation with high PgR and low S phase. Int J Cancer (1995) 0.95
Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur J Hum Genet (2001) 0.95
Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer (2001) 0.94
The effect of mismatch repair deficiency on tumourigenesis; microsatellite instability affecting genes containing short repeated sequences. Int J Oncol (2000) 0.94
Loss of heterozygosity at chromosome 7q in human breast cancer: association with clinical variables. Anticancer Res (1997) 0.94
Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res (1999) 0.93
The volume-deficient orbit: clinical characteristics, surgical management, and results after extraperiorbital implantation of Silastic block. Br J Ophthalmol (1990) 0.93
Immature B cells in bone marrow express Fas/FasL. Scand J Immunol (2000) 0.92
Mitochondria, cell surface, and carcinogenesis. Int Rev Cytol Suppl (1983) 0.92
Multiple chromosomal rearrangements in a spontaneously arising t(6;7) rat immunocytoma juxtapose c-myc and immunoglobulin heavy chain sequences. Proc Natl Acad Sci U S A (1986) 0.91
Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer. Int J Cancer (1989) 0.91
Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat (1998) 0.90
Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer (2000) 0.90
Drosophila homolog of the murine Int-1 protooncogene. Proc Natl Acad Sci U S A (1988) 0.89
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet (1998) 0.88
Gene localization on sorted chromosomes: definitive evidence on the relative positioning of genes participating in the mouse plasmacytoma-associated typical translocation. Proc Natl Acad Sci U S A (1985) 0.87
Toxic and mutagenic effects of carcinogens on the mitochondria of Saccharomyces cerevisiae. Mol Gen Genet (1979) 0.87
TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer (1996) 0.86
One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications? Cytometry (1992) 0.86
Amplification of c-myc and pvt-1 homologous sequences in acute nonlymphatic leukemia. Leuk Res (1988) 0.86
Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry (1992) 0.84
Nucleotide sequence of the rat Bmyc gene. Oncogene (1989) 0.84
Symbiotic and saprophytic survival of three unmarked Rhizobium leguminosarum biovar trifolii strains introduced into the field. Environ Microbiol (2005) 0.84
Identification of a breast tumor with microsatellite instability in a potential carrier of the hereditary non-polyposis colon cancer trait. Clin Genet (1995) 0.84
Screening as a prognostic factor in cervical cancer: analysis of survival and prognostic factors based on Icelandic population data, 1964-1988. Gynecol Oncol (1991) 0.84
Survey of prescriptions for peptic ulcer drugs (ACT class AOB2) in Iceland. Scand J Gastroenterol (1994) 0.83
Human interdigitating dendritic cells induce isotype switching and IL-13-dependent IgM production in CD40-activated naive B cells. J Immunol (2000) 0.83
Who becomes a sperm donor: personality characteristics in a national sample of identifiable donors. BJOG (2011) 0.83
Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer (1995) 0.83
High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Cancer Res (1998) 0.82
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers. Oncogene (1998) 0.82
Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group. Eur J Cancer (1994) 0.82
Similarities and differences in the regulation of N-myc and c-myc genes in murine embryonal carcinoma cells. Exp Cell Res (1987) 0.82
Loss of heterozygosity on chromosome arm 3p in nasopharyngeal carcinoma. Genes Chromosomes Cancer (1996) 0.82
Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst (1991) 0.81
Personality characteristics in a Swedish national sample of identifiable oocyte donors. BJOG (2011) 0.81